-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

364 Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 TrialClinically Relevant Abstract

Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Multiple Myeloma: Clinical and Epidemiological: Advancing Minimal Residual Disease (MRD): Detection, Impact on Prognosis and Treatment Decisions
Hematology Disease Topics & Pathways:
Research, Clinical trials, Combination therapy, Adult, Clinical Research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies, Study Population, Human, Measurable Residual Disease
Saturday, December 7, 2024: 4:45 PM

Elias K. Mai, MD1*, Hans Salwender, MD2*, Michael Hundemer, MD3*, Uta Bertsch, MD4*, Ema Pozek5*, Axel Benner6*, Roland Fenk, MD, PhD7*, Britta Besemer, MD8*, Christine Hanoun9*, Roland Schroers, MD10*, Ivana von Metzler, MD11*, Mathias Hänel, MD12, Christoph Mann, MD13*, Lisa Leypoldt, MD14*, Bernhard Heilmeier15*, Stefanie Huhn, PhD16*, Sabine Vogel, PhD17*, Christof Scheid18*, Igor Wolfgang Blau, MD, PhD19*, Steffen Luntz, MD20*, Niels Weinhold, PhD21*, Tobias A.W. Holderried, MD22*, Karolin Trautmann-Grill23*, Deniz Gezer, MD24*, Maika Klaiber-Hakimi25*, Martin Mueller, MD26*, Evgenii Shumilov27*, Wolfgang Knauf, MD28*, Christian Sebastian Michel, MD29*, Thomas Geer, MD30, Hendrik Riesenberg31*, Christoph Lutz32*, Marc S. Raab21*, Martin Hoffmann33*, Katja C. Weisel, MD34 and Hartmut Goldschmidt, MD21

1Medicine V, University Hospital Heidelberg, Heidelberg, Germany
2Asklepios Tumorzentrum Hamburg, Asklepios Hospital Hamburg Altona and St. Georg, Hamburg, Germany
3Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
4Internal Medicine V, Hematology, Oncology and Rheumatology, GMMG Studygroup, Heidelberg University Hospital, Heidelberg, Germany
5German Cancer Research Center, Heidelberg, DEU
6Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
7Department of Haematology, Oncology, and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany
8Department of Internal Medicine II, University Hospital Tübingen, Tübingen, Germany
9Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer consortium (DKTK partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany
10Knappschaftskrankenhaus Bochum, University Hospital Bochum, Bochum, Germany
11Department of Medicine II – Hematology and Oncology, Goethe-University Frankfurt, University Hospital, Frankfurt am Main, Germany
12Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany
13Department of Haematology, Oncology and Immunology, Philipps-University Marburg, Marburg, Germany
14University Medical Center Hamburg Eppendorf, Hamburg, Germany
15Clinic for Oncology and Hematology, Hospital Barmherzige Brueder Regensburg, Regensburg, Germany, Regensburg, DEU
16Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany
17Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany, Heidelberg, Germany
18Cologne University Hospital, Cologne, Germany
19Medizinische Klinik m. S. Hämatologie , Onkologie und Tumorimmunologie, Berlin, Germany, Berlin, Germany
20Coordination Centre for Clinical Trials (KKS), Heidelberg, Germany
21Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
22Universitaetsklinikum Bonn (UKB), Bonn, Germany
23University Hospital Carl Gustav Carus, Dresden, Germany
24Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, DEU
25Clinic for Hematology, Oncology and Palliative Care, Marien Hospital Düsseldorf, Düsseldorf, Germany, Duesseldorf, DEU
26Klinikum Siloah Hannover, Hannover, Germany, Hannover, AL, DEU
27Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany
28Center for Hematology and Oncology, Bethanien, Frankfurt a.M., Germany, Frankfurt a.M., Germany
29Department of Internal Medicine III, University Hospital Mainz, Mainz, Germany
30Medizinische Klinik Schwäbisch-Hall, Schwabisch Hall, DEU
31Hematology / Oncology Center, Bielefeld, Germany, Bielefeld, Germany
32Hematology / Oncology Center, Koblenz, Germany, Koblenz, Germany
33Medical Clinic A, Clinic Ludwigshafen, Ludwigshafen, Germany, Ludwigshafen, Germany
34Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Background: Minimal residual disease negativity (MRDneg) in the bone marrow is associated with improved survival outcomes in patients (pts) with newly diagnosed multiple myeloma (NDMM). The randomized, multicenter phase 3 GMMG-HD7 trial (NCT03617731) demonstrated that addition of anti-CD38 monoclonal antibody isatuximab (Isa) to standard of care treatment lenalidomide, bortezomib, and dexamethasone (RVd) in pts with transplant-eligible NDMM significantly increased MRDneg rates after induction therapy (Isa-RVd 50% vs. RVd 36%, OR 1.82, 95% CI 1.33-2.48, p<0.001; Goldschmidt H et al., 2022, Lancet Haematol.). Here we present landmark analyses exploring the impact of MRDneg and continued MRDneg on progression-free survival (PFS).

Methods: Pts with transplant-eligible NDMM were stratified by Revised International Staging System (Palumbo A et al., 2015, J Clin Oncol.) and equally randomized to receive three 42-day cycles of RVd (lenalidomide 25 mg/d po, d1-14 and d22-35; bortezomib 1.3 mg/m2 SC d1, 4, 8, 11, 22, 25, 29, 32; dexamethasone 20 mg/d po, d1-2, 4-5, 8-9, 11-12, 15, 22-23, 25-26, 29-30, 32-33). In the Isa-RVd arm, Isa 10 mg/kg IV, cycle 1: d 1, 8, 15, 22, 29; cycles 2-3: d 1, 15, 29 was added. Following induction therapy, pts underwent stem cell collection, high-dose melphalan therapy (200 mg/m2) and autologous hematopoietic stem cell transplant. Pts were then randomized to receive maintenance with either lenalidomide alone (10 mg/d po continuously) or in combination with Isa (10 mg/kg IV., cycle 1: d 1, 8, 15, 22; cycles 2-3: d 1, 15; cycles 4-39: d 1) for up to 36 months. MRDneg from bone marrow samples was assessed by next-generation flow cytometry (sensitivity 10-5) independent of International Myeloma Working Group response rates. Continued MRDneg status was defined as MRDneg persisting from post induction to post intensification. PFS was defined as time from respective landmark to progression or death from any cause, whichever occurred first. Data cut-off for the present analyses was January 31, 2024.

Results: Between Oct 2018 and Sep 2020, 662 pts were included in the trial. The intention-to-treat analysis comprised 660 pts (Isa-RVd: 331 and RVd: 329). Baseline characteristics were well balanced. PFS results from first randomization are reported separately.

At this respective PFS landmark analyses post induction and post intensification, higher proportions of patients in the Isa-RVd arm vs. RVd arm had improved rates of MRDneg and continued MRDneg. PFS analyses from end of induction therapy comprised 282 MRDneg pts (Isa-RVd: 166/55% and RVd:116/41%) and 304 MRD positive (MRDpos) pts (Isa-RVd: 136/45% and RVd: 168/59%). PFS was significantly longer in pts achieving MRDneg (HR 0.38, 95% CI 0.26-0.55; p<0.001) with 3-year PFS rates from end of induction therapy of 88% (95% CI 85–92) for MRDneg pts and 71% (95% CI 66–77) for MRDpos pts. Among MRDneg pts, PFS was similar in the Isa-RVd and RVd arms (HR 1.12, 95% CI 0.60-2.11, p=0.72). In MRDpos pts, PFS was significantly longer with Isa-RVd vs. RVd (HR 0.64, 95% CI 0.43-0.96; p=0.03). Analyses of the impact of continued MRDneg on PFS from start of maintenance therapy included 227 pts with continued MRDneg (Isa-RVd: 138/53% and RVd:89/38%) and 267 without continued MRDneg (Isa-RVd: 122/47% and RVd: 145/62%). PFS was significantly prolonged in pts with continued MRDneg compared with those without continued MRDneg (HR 0.41, 95% CI 0.25-0.65; p<0.001). 3-year PFS rates from start of maintenance therapy were 90% (95% CI 86-94) in pts with continued MRDneg and 77% (95% CI 72–83) in pts without continued MRDneg. Pts in the Isa-RVd and RVd arm with continued MRDneg had similar PFS (HR 1.13, 95% CI 0.49-2.61; p=0.77). Among pts without continued MRDneg, PFS was longer in the Isa-RVd arm vs. the RVd arm (HR 0.68, 95% CI 0.41-1.13; p=0.14).

Multivariable analyses including induction treatment arm, key baseline patient characteristics and disease risk factors confirmed the significant prognostic impact of MRDneg on PFS from end of induction therapy (HR 0.37, 95% CI 0.26-0.55; p<0.001) and continued MRDneg on PFS from start of maintenance therapy (HR 0.44, 95% CI 0.27-0.72; p=0.001).

Conclusions: More pts achieved MRDneg and continued MRDneg with Isa-RVd vs. RVd, while the PFS benefit after obtaining MRDneg and continued MRDneg was similar in both arms. For pts who have MRDpos and continued MRDpos, the addition of Isa to RVd is associated with a favorable PFS vs. RVd alone.

Disclosures: Mai: Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Bistol Myers Squibb/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses, Research Funding; GlaxoSmithKline (GSK): Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel accomodations and expenses, Research Funding; Janssen-Cilag: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel accomodations and expenses, Research Funding; Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel accomodations and expenses, Research Funding; Stemline: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel accomodations and expenses; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel accomodations and expenses, Research Funding; Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees. Salwender: Stemline: Honoraria; Roche: Honoraria; Takeda: Honoraria; Chugai: Honoraria; Janssen: Honoraria, Other: Travel grant; Oncopeptides: Honoraria; Pfizer: Honoraria; Sanofi: Honoraria, Other: Travel grant; GlaxoSmithKline: Honoraria; Bristol Myers Squibb/Celgene: Honoraria, Other: Travel grant; Amgen: Honoraria, Other: Travel grant; AbbVie: Honoraria; Sebia: Honoraria. Hundemer: BeiGene: Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; BMS/Celgene: Other: travel expenses, Research Funding; Becton Dickinson: Membership on an entity's Board of Directors or advisory committees; Janssen: Research Funding; Novartis: Research Funding; Sanofi: Research Funding; Alexion: Research Funding; Roche: Research Funding. Fenk: GlaxoSmithKline (GSK): Other: travel expenses; Pfizer: Honoraria; Amgen: Honoraria; Janssen: Honoraria, Other: travel expenses; Sanofi: Honoraria; Takeda: Honoraria; BMS/Celgene: Honoraria, Other: travel accommodation and expenses. Besemer: GlaxoSmithKline: Honoraria; Pfizer: Honoraria; Oncopeptides: Honoraria; Janssen: Honoraria; Takeda: Honoraria; AMGEN: Honoraria. Schroers: Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria; Takeda: Honoraria; Kite/Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Honoraria, Membership on an entity's Board of Directors or advisory committees. von Metzler: GlaxoSmithKline (GSK): Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Consultancy, Membership on an entity's Board of Directors or advisory committees; Stemline: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees. Hänel: Jazz Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bayer Vital: Consultancy, Membership on an entity's Board of Directors or advisory committees; BristolMyersSquibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BristolMyersSquibb/Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Falk Foundation: Honoraria; Sanofi-Aventis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gilead Sciences: Honoraria; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Kite/Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Sobi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Consultancy, Membership on an entity's Board of Directors or advisory committees. Mann: BristolMyersSquibb: Consultancy; Janssen: Consultancy; Celgene: Consultancy; Sanofi: Consultancy. Leypoldt: Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive: Honoraria; Abbvie: Honoraria, Research Funding; BMS/Celgene: Honoraria; Pfizer: Honoraria; Oncopeptides: Other: travel expenses; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Heilmeier: Sanofi-Aventis: Consultancy. Scheid: Takeda: Honoraria, Other: Travel accomodation and expanses, Research Funding; Novartis: Other: Travel accomodation and expanses, Research Funding; Sanofi: Honoraria; Oncopeptides: Honoraria; Pfizer: Honoraria; Janssen: Honoraria, Other: Travel accomodation and expanses, Research Funding; GSK: Honoraria; BMS: Honoraria, Other: Travel accomodation and expanses; Amgen: Honoraria; Abbvie: Honoraria. Weinhold: BMS/Celgene: Research Funding; GlaxoSmithKline (GSK): Membership on an entity's Board of Directors or advisory committees; Sanofi-Aventis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; The Binding Site: Research Funding. Holderried: GlaxoSmithKline (GSK): Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; Jazz Pharmaceuticals: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; Kite/Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Otsuka Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbvie: Other: travel expenses; Janssen: Other: travel expenses; Astellas Pharma: Other: travel expenses; Neovii: Other: travel expenses; Immatics: Other: travel expenses; Sobi: Other: travel expenses; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses. Trautmann-Grill: Amgen, Grifols, GSK, Novartis, Sanofi, SOBI: Consultancy; Amgen, Grifols, GSK, Novartis, Sanofi, SOBI, Takeda: Honoraria; Roche, Grifols: Speakers Bureau. Gezer: Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Consultancy; Pfizer: Membership on an entity's Board of Directors or advisory committees; Janssen/Cilag: Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy. Klaiber-Hakimi: Sanofi: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Beigen: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees. Mueller: Abbvie: Consultancy; AstraZeneca: Consultancy, Honoraria; BMS: Consultancy, Honoraria; GlaxoSmithKline (GSK): Consultancy; Janssen: Consultancy, Honoraria; MSD: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Servier: Honoraria; Sobi: Honoraria. Shumilov: Oncopeptides: Consultancy, Honoraria, Other: Travel and congress support; Incyte: Honoraria; BMS: Consultancy, Honoraria; Gilead: Consultancy, Honoraria, Other: Travel and congress support; Pfizer: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Other: Travel and congress support; Stemline: Consultancy, Honoraria; Sanofi-Aventis: Consultancy, Honoraria, Other: Congress support. Knauf: Amgen: Honoraria; Abbvie: Honoraria; AstraZeneca: Consultancy, Honoraria; Beigene: Consultancy, Honoraria; BMS: Honoraria; BMS/Celgene: Honoraria; Janssen: Consultancy, Honoraria; Sanofi: Honoraria. Michel: Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; Oncopeptides: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Other: travel expenses; GlaxoSmithKline (GSK): Honoraria, Other: travel expenses; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses. Lutz: Abbvie: Membership on an entity's Board of Directors or advisory committees; Apogepha: Membership on an entity's Board of Directors or advisory committees; EISAI: Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline (GSK): Membership on an entity's Board of Directors or advisory committees; Ipsen: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Speakers Bureau; Pfizer: Speakers Bureau. Raab: Oncopeptides: Consultancy, Honoraria, Other: travel expenses; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses, Research Funding; Heidelberg Pharma: Research Funding; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees. Hoffmann: Sanofi-Aventis: Consultancy; Janssen: Honoraria, Other: travel expenses. Weisel: Amgen: Consultancy, Honoraria, Other: Research grant to institution; AbbVie: Other: Research grant to institution; Bristol Myers Squibb/Celgene: Consultancy, Honoraria, Other: Research grant to institution; GlaxoSmithKline: Consultancy, Honoraria, Other: Research grant to institution; Janssen: Consultancy, Honoraria, Other: Research grant to institution; Sanofi: Consultancy, Honoraria, Other: Research grant to institution; Adaptive Biotechnologies: Consultancy, Honoraria; AstraZeneca: Honoraria; BeiGene: Consultancy, Honoraria; Karyopharm: Consultancy, Honoraria; Menarini: Consultancy, Honoraria; Novartis: Honoraria; Oncopeptides: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Stemline: Honoraria; Roche Pharma: Consultancy, Honoraria; Regeneron: Consultancy. Goldschmidt: Novartis: Honoraria, Other: Support for attending meetings and/or travel, Research Funding; Celgene: Research Funding; Pfizer: Honoraria, Other: Support for attending meetings and/or travel, Research Funding; Chugai: Honoraria, Other: Grants and/or provision of Investigational Medicinal Product; Bristol Myers Squibb/Celgene: Other: Grants and/or provision of Investigational Medicinal Product; Karyopharm: Research Funding; Merck Sharp and Dohme (MSD): Research Funding; Mundipharma GmbH: Other: Grants and/or provision of Investigational Medicinal Product; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Grants and/or provision of Investigational Medicinal Product; support for attending meetings and/or travel, Research Funding; Takeda: Research Funding; Array Biopharma/Pfizer: Other: Grants and/or provision of Investigational Medicinal Product; Adaptive Biotechnologies: Membership on an entity's Board of Directors or advisory committees; GlycoMimetics Inc.: Research Funding; Heidelberg Pharma: Research Funding; Hoffmann-La Roche: Research Funding; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Grants and/or provision of Investigational Medicinal Product; support for attending meetings and/or travel, Research Funding; GlaxoSmithKline (GSK): Honoraria, Other: Support for attending meetings and/or travel, Research Funding; Millennium Pharmaceuticals Inc.: Research Funding; Molecular Partners: Research Funding; MorphoSys AG: Research Funding; Incyte Corporation: Research Funding; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings and/or travel, Research Funding; Dietmar Hopp Foundation: Other: Grants and/or provision of Investigational Medicinal Product; Johns Hopkins University: Other: Grants and/or provision of Investigational Medicinal Product; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings and/or travel; grants and/or provision of Investigational Medicinal Product, Research Funding.

OffLabel Disclosure: Isatuximab is not approved for upfront treatment in patients with newly-diagnosed multiple myeloma.

See more of: 653. Multiple Myeloma: Clinical and Epidemiological: Advancing Minimal Residual Disease (MRD): Detection, Impact on Prognosis and Treatment Decisions
See more of: Oral and Poster Abstracts
<< Previous Abstract | Next Abstract >>
*signifies non-member of ASH